title: p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.
abstract: Genomic analysis and protein expression assimilate triple-negative breast cancers (TNBC) with basal-like breast tumors. TNBCs, however, have proved to encompass also tumors with normal-like phenotype and known to have favorable prognosis and to respond to chemotherapy. In a recent paper, we have provided evidence that p53 status is able to subdivide TNBCs into two distinct subgroups with different outcome, and consistent with basal- and normal-like phenotypes. Based on this finding, we explored the contribution of p53 status in predicting the response to adjuvant CMF or CMF followed doxorubicin chemotherapy of a group of TNBC patients. Results indicated that TNBC patients with a p53-positive tumor had a shorter relapse-free and overall survival than patients carrying a p53-negative TNBC, corroborating our hypothesis about the relationship between TNBC phenotype (basal-like versus normal-like) and p53 status as predictor of response to anthracycline/CMF-based chemotherapy.
authors.affiliation: Unit of Medical Statistics, Biometry and Bioinformatics "G.A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Electronic address: danila.coradini@gmail.com.
authors.forename: Danila
authors.initials: D
authors.lastname: Coradini
authors.affiliation: Unit of Medical Statistics, Biometry and Bioinformatics "G.A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors.forename: Elia
authors.initials: E
authors.lastname: Biganzoli
authors.affiliation: Unit of Medical Statistics, Biometry and Bioinformatics "G.A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
authors.forename: Ilaria
authors.initials: I
authors.lastname: Ardoino
authors.affiliation: Unit of Medical Statistics, Biometry and Bioinformatics "G.A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
authors.forename: Federico
authors.initials: F
authors.lastname: Ambrogi
authors.affiliation: Unit of Medical Statistics, Biometry and Bioinformatics "G.A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Boracchi
authors.affiliation: Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors.forename: Romano
authors.initials: R
authors.lastname: Demicheli
authors.affiliation: Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Daidone
authors.affiliation: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors.forename: Angela
authors.initials: A
authors.lastname: Moliterni
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D017024:Chemotherapy, Adjuvant / Q000706:statistics & numerical data; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D016158:Genes, p53; D006801:Humans; D008408:Mastectomy; D008727:Methotrexate / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000235:genetics; D010641:Phenotype; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis; D059005:Topoisomerase II Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome; D064726:Triple Negative Breast Neoplasms / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; C495901:TP53 protein, human; D059005:Topoisomerase II Inhibitors; D016159:Tumor Suppressor Protein p53; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
keywords: Adjuvant chemotherapy; Breast cancer; Triple negative; p53 status